Omthera Pharmaceuticals, Inc., a Bedminster NJ-based pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia, has raised $33.9m in a Series B funding round.
The round was led by new investor New Enterprise Associates, with participation from existing investor, Sofinnova Partners.
The company intends to use the new capital raised to fund the Phase 3 clinical development of its novel Omega-3 fatty acid compound, Epanova™, and for general corporate purposes.
With this latest round, Omthera has raised approximately $40.4m in venture capital since commencement of operations in 2009.
In conjunction with the funding, David M. Mott, a General Partner at NEA, has joined the company’ s Board of Directors.
Founded in 2008 by CEO Jerry Wisler, Omthera is dedicated to developing innovative therapies for patients who have elevated triglyceride levels and increased risk of cardiovascular disease.